AstraZeneca and Abbott end license agreement for the development of Certriad
Posted: 3 January 2011 | | No comments yet
AstraZeneca has notified Abbott that it will discontinue the development of CERTRIAD on 22 January 2011…
AstraZeneca has notified Abbott that it will discontinue the development of CERTRIAD on 22 January 2011...
AstraZeneca announced today that it has notified Abbott that it will discontinue the development of CERTRIAD (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on 22 January 2011.
A Complete Response Letter (CRL) for the CERTRIAD New Drug Application (NDA) was received from the U.S. Food and Drug Administration (FDA) on 30 March 2010.
The companies reached this decision after careful review and consideration of the CRL and the resulting regulatory delay, and have determined that the development of CERTRIAD is no longer commercially attractive.
AstraZeneca will continue to focus on other development priorities both within and outside of the cardiovascular disease therapeutic area.
